000283051 001__ 283051
000283051 005__ 20260103103702.0
000283051 0247_ $$2doi$$a10.1212/WNL.0000000000214490
000283051 0247_ $$2pmid$$apmid:41453122
000283051 0247_ $$2ISSN$$a0028-3878
000283051 0247_ $$2ISSN$$a1526-632X
000283051 037__ $$aDZNE-2025-01458
000283051 041__ $$aEnglish
000283051 082__ $$a610
000283051 1001_ $$00000-0003-3523-4520$$aBartels, Frederik$$b0
000283051 245__ $$aMemory Deficits in Cancer Patients With Serum NMDA Receptor Autoantibodies.
000283051 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2026
000283051 3367_ $$2DRIVER$$aarticle
000283051 3367_ $$2DataCite$$aOutput Types/Journal article
000283051 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767356344_32515
000283051 3367_ $$2BibTeX$$aARTICLE
000283051 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283051 3367_ $$00$$2EndNote$$aJournal Article
000283051 520__ $$aNeuronal autoantibodies are linked to cognitive impairment in neurologic diseases and can be associated with tumors. In patients with cancer, IgA/IgM N-Methyl-D-Aspartate receptor (NMDAR) autoantibodies are most common, yet their clinical relevance is unclear. We assessed cognitive function in cancer patients with serum NMDAR autoantibodies and compared the results with matched controls.For this cross-sectional case-control study in Germany, we recruited 1,055 patients with cancer and tested for neuronal serum autoantibodies. Cognitive assessment was performed blinded to antibody status and after excluding patients with potential confounders of cognitive dysfunction. The tests included verbal memory (Rey Auditory Verbal Learning Test), visuospatial memory (Rey-Osterrieth Complex Figure), and working memory.Fifty-six patients with IgA/IgM NMDAR autoantibodies (median age 61.0 years [28.0-86.0], 35.7% female) were matched 1:1 to autoantibody-negative patients by age, sex, cancer type, and stage. Autoantibody-positive patients showed impairments in verbal memory (mean score ± SD: 9.7 ± 3.6 vs 11.4 ± 3.2; p = 0.01; Cohen d = 0.49), visuospatial memory (19.4 ± 7.0 vs 22.6 ± 5.6; p = 0.01; d = 0.50), and working memory (6.2 ± 1.9 vs 7.0 ± 2.1; p = 0.04; d = 0.40). Memory function decreased with increasing IgA NMDAR autoantibody levels. Both groups performed similarly on measures of attention, executive function, and verbal fluency.Serum NMDAR autoantibodies are associated with isolated memory deficits in patients with cancer and might serve as a potential biomarker for cancer-related cognitive impairment.
000283051 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283051 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283051 650_7 $$2NLM Chemicals$$aAutoantibodies
000283051 650_7 $$2NLM Chemicals$$aReceptors, N-Methyl-D-Aspartate
000283051 650_2 $$2MeSH$$aHumans
000283051 650_2 $$2MeSH$$aFemale
000283051 650_2 $$2MeSH$$aMale
000283051 650_2 $$2MeSH$$aAutoantibodies: blood
000283051 650_2 $$2MeSH$$aMiddle Aged
000283051 650_2 $$2MeSH$$aReceptors, N-Methyl-D-Aspartate: immunology
000283051 650_2 $$2MeSH$$aAged
000283051 650_2 $$2MeSH$$aCross-Sectional Studies
000283051 650_2 $$2MeSH$$aCase-Control Studies
000283051 650_2 $$2MeSH$$aAdult
000283051 650_2 $$2MeSH$$aMemory Disorders: blood
000283051 650_2 $$2MeSH$$aMemory Disorders: immunology
000283051 650_2 $$2MeSH$$aMemory Disorders: etiology
000283051 650_2 $$2MeSH$$aNeoplasms: blood
000283051 650_2 $$2MeSH$$aNeoplasms: complications
000283051 650_2 $$2MeSH$$aNeoplasms: immunology
000283051 650_2 $$2MeSH$$aNeoplasms: psychology
000283051 650_2 $$2MeSH$$aAged, 80 and over
000283051 650_2 $$2MeSH$$aNeuropsychological Tests
000283051 7001_ $$aTapuc, Andreea$$b1
000283051 7001_ $$aRentzsch, Kristin$$b2
000283051 7001_ $$0P:(DE-2719)9002020$$aDuong, Sophie L$$b3$$udzne
000283051 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b4
000283051 7001_ $$0P:(DE-2719)9001141$$aFinke, Carsten$$b5
000283051 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000214490$$gVol. 106, no. 2, p. e214490$$n2$$pe214490$$tNeurology$$v106$$x0028-3878$$y2026
000283051 909CO $$ooai:pub.dzne.de:283051$$pVDB
000283051 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002020$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283051 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283051 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283051 9141_ $$y2026
000283051 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2025-01-02$$wger
000283051 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000283051 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2025-01-02
000283051 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000283051 980__ $$ajournal
000283051 980__ $$aVDB
000283051 980__ $$aI:(DE-2719)1810003
000283051 980__ $$aUNRESTRICTED